Cemiplimab for Metastatic Basal Cell Carcinoma: Exploring the Data With Karl Lewis, MD

Cemiplimab, a programmed cell death protein 1 (PD-1) inhibitor, was approved in 2021 as the first and only systemic therapy to demonstrate clinical benefit among patients with advanced basal cell carcinoma (BCC) previously treated with hedgehog pathway inhibitor (HHI) therapy. At the American Association for Cancer Research (AACR) Annual Meeting in April, Dr. Karl Lewis, Professor in the Division of Medical Oncology at the University of Colorado, presented the primary results of the EMPOWER-BCC ...

Continue reading

Cemiplimab Approval for Locally Advanced/Metastatic Basal Cell Carcinoma

Recently, the FDA granted approval to cemiplimab (Libtayo®, Regeneron Pharmaceuticals) for the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) who were previously treated with a hedgehog pathway inhibitor (HHI) or who are ineligible for HHI therapy. In this interview, Karl Lewis, MD, Professor of Medical Oncology at the University of Colorado Anschutz Medical Campus and one of the investigators of Study 1620 (NCT03132636), on which the approval was based, spe...

Continue reading

Cemiplimab-rwlc Approved for Locally Advanced/Metastatic Basal Cell Carcinoma

The FDA has now approved cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals) for patients with locally advanced or metastatic basal cell carcinoma (BCC) who received prior treatment with a hedgehog pathway inhibitor (HHI) and those who are ineligible for HHI therapy. Cemiplimab is the first immunotherapy to be approved for patients with advanced BCC. "Cemiplimab, an antibody to programmed cell death protein 1 (PD-1), is an established therapy approved for treatment of advanced cutaneous squamo...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.